{
    "body": "Is flibanserin effetive for Hypoactive Sexual Desire Disorder? ", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20646181", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23421417", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25659981", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25187905", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24281236", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22727480"
    ], 
    "ideal_answer": [
        "Yes, flibanserin, a novel serotonin (5-HT)(1A) agonist and 5-HT(2A) antagonist, has been shown to increase sexual desire and reduce distress in women with Hypoactive Sexual Desire Disorder."
    ], 
    "exact_answer": "yes", 
    "concepts": [
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4266735", 
        "http://www.biosemantics.org/jochem#4266735", 
        "http://www.disease-ontology.org/api/metadata/DOID:13868"
    ], 
    "type": "yesno", 
    "id": "56bb6b0eac7ad1001900000e", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 132, 
            "text": "Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25659981", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 186, 
            "text": "Flibanserin is a novel multifunctional serotonin agonist and antagonist (MSAA) that improves sexual functioning in premenopausal women who suffer from reduced sexual interest and desire.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25659981", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 282, 
            "offsetInEndSection": 518, 
            "text": "Flibanserin is a novel, non-hormonal drug for the treatment of HSDD in pre- and postmenopausal women, although the application submitted to the U.S. Food and Drug Administration by Sprout Pharmaceuticals is only for premenopausal women.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25187905", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1455, 
            "offsetInEndSection": 1717, 
            "text": "CONCLUSIONS: In naturally postmenopausal women with HSDD, flibanserin, compared with placebo, has been associated with improvement in sexual desire, improvement in the number of SSEs, and reduced distress associated with low sexual desire, and is well tolerated.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24281236", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 157, 
            "text": "INTRODUCTION: Flibanserin is a mixed 5-HT1A agonist/5-HT2A antagonist that has been developed for the treatment of hypoactive sexual desire disorder in women", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23421417", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 204, 
            "text": "BACKGROUND: Flibanserin, a novel serotonin (5-HT)(1A) agonist and 5-HT(2A) antagonist, has been shown to increase sexual desire and reduce distress in women with Hypoactive Sexual Desire Disorder (HSDD). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727480", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 431, 
            "text": "Hypoactive sexual desire disorder (HSDD) is the most commonly described form of female sexual dysfunction. There is currently no pharmacological therapy approved to treat HSDD, and therefore, there is an unmet medical need for the development of efficacious treatment alternatives. Flibanserin is a novel, non-hormonal drug for the treatment of HSDD in pre- and postmenopausal women, although the application submitted to the U.S. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25187905", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1562, 
            "offsetInEndSection": 1982, 
            "text": "Sexual function adverse events across flibanserin groups were generally comparable to placebo.Although these studies were not designed or powered to compare sexual function outcomes, results suggested a potential benefit of flibanserin on sexual function, particularly on female sexual desire, and provided a rationale to evaluate the efficacy of flibanserin as a treatment for female hypoactive sexual desire disorder.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20646181", 
            "endSection": "abstract"
        }
    ]
}